A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer - Wang, Jing-Jing; Siu, Michelle Kwan-Yee; Jiang, Yu-Xin; Leung, Thomas Ho-Yin; Chan, David Wai; Wang, Huo-Gang; Ngan, Hextan Yuen-Sheung; Chan, Karen Kar-Loen (Biomolecules (Basel, Switzerland), 2021)
Keywords: Animals; Annexin V; Antibodies; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Apoptosis; Benzophenanthridines - administration & dosage; Benzophenanthridines - pharmacology; Cancer therapies; CD3 antigen; CD4 antigen; CD8 antigen; Cell culture; Cell death; Cell Line, Tumor; Cell proliferation; Cell Proliferation - drug effects; Cell Survival - drug effects; Chemokines; Clinical outcomes; CXCL10 protein; CXCL11 protein; Drug Synergism; Female; Flow cytometry; Gene expression; Gene Expression Regulation, Neoplastic - drug effects; Glutaminase; Glutaminase - genetics; Glutamine; glutamine metabolism; Granzyme B; Humans; Immune checkpoint; Immune Checkpoint Inhibitors - administration & dosage; Immune Checkpoint Inhibitors - pharmacology; Immune response; Immune system; Immunotherapy; Isotypes; Kidneys; Lung cancer; Lymphocytes; Lymphocytes T; Medical prognosis; Metabolism; Metastases; Mice; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - genetics; Ovarian Neoplasms - metabolism; PD-L1 protein; T cells; Treatment Outcome; Tumor cells; Tumor microenvironment; Tumor Microenvironment - drug effects; Tumorigenesis; Tumors; Xenograft Model Antitumor Assays; Xenografts; Hong Kong China; Canada; United States--US; glutamine metabolism; T cells; ovarian cancer; immunotherapy